This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hereng, T. Articles by Hatron, P.-Y. Search for Related Content PubMed PubMed Citation Articles by Hereng, T. Articles by Hatron, P.-Y. Social Bookmarking                         What's this?

Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients

Department of Internal Medicine

M. Lambert

Department of Internal Medicine, m-lambert{at}chru-lille.fr

E. Hachulla

Department of Internal Medicine

M. Samor

Department of Internal Medicine

S. Dubucquoi

Immunology Laboratory

C. Caron

Hemostasis Laboratory, University Hospital of Lille, Faculty of Medicine and Lille University, 59035 Lille Cedex, France

D. Launay

Department of Internal Medicine

S. Morell-Dubois

Department of Internal Medicine

V. Queyrel

Department of Internal Medicine

P.-Y. Hatron

Department of Internal Medicine

One hundred and three consecutive asymptomatic anti-phospholipid (aPL) antibody-positive carriers, taking aspirin (n = 75) or not (n = 28), were studied retrospectively to determine whether aspirin could provide primary prevention of anti-phospholipid syndrome (APS) symptoms. All patients positive for anti-cardiolipin antibodies (aCL; >25 UGPL or UMPL) and/or lupus anti-coagulant were followed for a mean of 64 ± 24.7 months.

Among aPL-positive patients, 37 had systemic lupus erythematosus (SLE), 20 had prolonged activated partial thromboplastin times, 19 had other connective tissue diseases, 16 had autoimmune thrombocytopenia (AIT), 11 had diverse diseases. Nineteen patients experienced thrombotic event(s) during follow-up. Clinical features, biological parameters and hydroxychloroquine use were comparable for the two groups, but thrombotic events differed (log-rank test; P = 0.02). Four of the 10 SLE patients not taking aspirin developed thrombosis compared with 3/27 SLE patients taking aspirin (log-rank test; P = 0.03). Anti-phospholipid -positive patients with AIT developed fewer thromboses while taking aspirin (log-rank test; P = 0.01). In conclusion, aPL-positive SLE and AIT patients should take aspirin to prevent APS manifestations. Prospective therapeutic trials are needed to confirm aspirin's prophylactic role in such patients. Lupus (2008) 17, 11—15.

Key Words: anti-phospholipid antibody syndrome • aspirin • prevention • systemic lupus erythematosus

Lupus, Vol. 17, No. 1, 11-15 (2008)
DOI: 10.1177/0961203307084724


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. O. EILERTSEN, A. BECKER-MEROK, and J. C. NOSSENT The Influence of the 1997 Updated Classification Criteria for Systemic Lupus Erythematosus: Epidemiology, Disease Presentation, and Patient Management J Rheumatol, March 1, 2009; 36(3): 552 - 559. [Abstract] [Full Text] [PDF]

				A. Metjian and W. Lim ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis? Hematology, January 1, 2009; 2009(1): 247 - 249. [Abstract] [Full Text] [PDF]